The Administrative Core will be responsible for the overall management of this IPCAVD program according to PAR-06-286. The Administrative Core will be responsible for interacting with the DAIDS Program Officer and Staff as required by the U19 funding mechanism as a multi-project cooperative agreement between our team and NIH. The Administrative Core will also perform its duty to coordinate all aspects of routine program management on administrative, financial, regulatory, and clinical issues. The Administrative Core will organize and interact with external advisors, and host annual external reviews.
Aim 1 : To coordinate the interactions a) among scientists from different institutions included in the current program, and b) between our team and NIH personnel regarding efficient implementation of proposed plans and projects.
Aim 2 : To oversee all budgetary matters, including review and approval of subcontract agreements negotiated through the Project Management Group (PMG) of Project 3, and the monitoring of monthly expenses and preparation of various reports.
Aim 3 : To maintain records of pre-IND and IND application documents with the US FDA and coordinate efforts in IND filing and clinical protocol reviews required by different agencies, institutions, and committees.
Aim 4 : To work with HVTN to improve, implement, and execute the Clinical Development Plan including the timely start of clinical testing at HVTN of our modified multi-gene, polyvalent HIV vaccine formulation to be developed by this application.
Aim 5 : Information management: to provide bioinformatics and statistical support, to develop an Intellectual Property plan, and plans to promote data standardization, data and resource sharing.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082676-05
Application #
8499209
Study Section
Special Emphasis Panel (ZAI1-ESB-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$547,052
Indirect Cost
$323,657
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Suschak, John J; Wang, Shixia; Fitzgerald, Katherine A et al. (2015) Identification of Aim2 as a sensor for DNA vaccines. J Immunol 194:630-6
Pouliot, Kimberly; Buglione-Corbett, Rachel; Marty-Roix, Robyn et al. (2014) Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. Vaccine 32:5049-56
Chen, Yuxin; Vaine, Michael; Wallace, Aaron et al. (2013) A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol 87:10232-43
Buglione-Corbett, Rachel; Pouliot, Kimberly; Marty-Roix, Robyn et al. (2013) Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy. PLoS One 8:e74820
Pan, Ruimin; Sampson, Jared M; Chen, Yuxin et al. (2013) Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans. J Virol 87:10221-31
Marty-Roix, Robyn; Lien, Egil (2013) (De-) oiling inflammasomes. Immunity 38:1088-90
Wang, Zheng; Zhang, Mingshun; Wang, Yan et al. (2011) A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. J Virol Methods 171:183-9
Vaine, Michael; Duenas-Decamp, Maria; Peters, Paul et al. (2011) Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol 85:4927-36
Zolla-Pazner, Susan; Kong, X-P; Jiang, Xunqing et al. (2011) Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol 85:9887-98
Vaine, Michael; Wang, Shixia; Hackett, Anthony et al. (2010) Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28:2999-3007

Showing the most recent 10 out of 11 publications